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Most widely used illicit drug
Can be smoked, eaten, or in some rare cases liquid
form
Varies widely in cost and potency, but in general, most
cannabis available currently is far more potent than
cannabis consumed in 1960-70’s (4-5% THC vs 15-20%
THC)
Modern strains also lower in CBD (neuroprotective)









Infinite number of nicknames based on region and strain of
plant being referred to. Most common generic terms include
“weed” and “pot”
Most strains are variations of Cannabis Indica, Cannabis
Sativa, or some hybrid
Indica ~ “body high” relaxing, sedating
Sativa ~ “head high” psychedelic, mind altering
THC = main psychotropically active ingredient, most
concentrated in plant resin

 Indica

 Sativa

 Afghani

 Acapulco Gold

 Bubba Kush

 Island Sweet Skunk

 Northern Lights

 Purple Haze

 Purple Urkle

 Sour Diesel

 Hybrids
 Blue Dream
 Cannatonic
 OG Kush
 White Widow










Joints – Cannabis cigarettes
Blunts – Hollowed out cheap cigars filled with Cannabis and rewrapped
Bowls – Cannabis packed into the bowl of a pipe
Bong – Pipe with water filter element
Vaporizer – Heats Cannabis so that THC evaporates and can be inhaled
without burning plant material
Dabs – Highly concentrated resin “wax” (80-90% THC vs Hashish at 4050%). Wax can be “dabbed” onto bud or smoked directly via a “rig”

“Dime bag” = $10 worth
 “Dub” = $20 worth
 A gram
 “eighth” = 1/8 oz = 3.5 grams = $40 for fairly high
potency






Oil Extraction
Liquid Extraction
Supercritical CO2 Extraction












Anxiolysis
Drowsiness
Slowed motor response, delayed reflexes
Increased Appetite
Injected Sclera (blood shot eyes): may be independent of smoking. THC 
lower BP  vasodilation
Amotivation
Increased novelty (Golden Girls reruns)
Time Dilation “chronic”
“Paranoia” (usually refers to feelings of self consciousness as opposed to
frank delusions)
Psychosis







Conflicting Data from Research
Clear Cognitive effects with intoxication including tracking, motor
coordination, visual functions, and particularly complex tasks that
require divided attention
However, only modest impairments on actual road tests
“Experienced smokers who drive on a set course show almost no
functional impairment under the influence of marijuana, except when
it is combined with alcohol” (Sewell, et al. THE EFFECT OF CANNABIS COMPARED WITH ALCOHOL ON

DRIVING, Am J Addict. 2009; 18(3): 185–193.)







Alcohol users tend to underestimate their degree of
impairment
Cannabis users tend to overestimate their degree of
impairment
Driving and simulator studies show marijuana use by drivers
is likely to result in decreased speed and fewer attempts to
overtake, as well as increased “following distance”







Cannabis impairs automatic functions in driving but
not conscious control
Alcohol impairs conscious control but not so much
automatic functions
The synergistic impairment of automatic and conscious
functions is why even low doses of alcohol with
cannabis can lead to severe impairment










Multiple studies from around the world (US, Australia, Switzerland,
Sweden, etc…) seem to consistently find minimal danger with THC
blood level below 5ng/mL with sudden spike in danger above 5 ng/mL
In the US, 6 states with “per se” laws, typically with limit of 5 ng/mL
(Nevada and Ohio limit of 2 ng/mL)
12 states with “zero tolerance” laws
All other states (including CA) use DUI standards, field sobriety tests,
and “Drug Recognition Experts)
Criteria vary state by state, some convict with “any” impairment, other
require “substantial” or “significant”






Anti-nausea
Anti-spastic
Neuropathic pain
Appetite stimulation





Cesamet (Nabilone): synthetic based, capsules, FDA
approved for chemo-related nausea
Marinol (Dronabinol): FDA approved for AIDS related
weight loss and chemo related nausea, also synthetic,
not as potent as Nabilone







Dry mouth
Increased tremor in some Parkinson’s patients
Low blood pressure
Lightheadedness
Drowsiness






Anxiolysis
Anti-inflammation/Pain
Anti-Nausea
Neuro-protective (anti-seizure)




Epidiolex: FDA approved June 2018
Approved to treat Lennox-Gastaut syndrome or Dravet syndrome
based seizures



2002-2014, pregnant women in US based on aggregate data, increased
from 2.4% to 3.9%. (Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in marijuana use

among pregnant and nonpregnant reproductive-aged women, 2002-2014. JAMA. 2017;317(2):207-209.)






JAMA study, self report with toxicology testing, pregnant women in
Northern California
Kaiser Permanente population 2009-2016
Rates of use (defined as any use in the past 30 days) increased from
4.2% to 7.1 % (Wolff, et al. Trends in Self-reported and Biochemically Tested Marijuana Use Among Pregnant Females in

California From 2009-2016. JAMA. 2017;318(24):2490-2491.)



Colorado Based study found 50% increased
likelihood of low birth weight but not small for
gestational age, preterm birth, or neonatal
intensive care unit admission. 5.7% prevalence
rate of use
(J Pediatr. 2018 Jun;197:90-96. doi: 10.1016/j.jpeds.2018.02.005. Epub 2018 Mar 28.)



Another study found Maternal marijuana use was not associated with
a composite of small for gestational age, spontaneous preterm birth,
or hypertensive disorders of pregnancy. However, it was associated
with an increased risk of neonatal morbidity. aOR of 3.11 for any form
of complication (pulmonary morbidity, necrotizing enterocolitis,
seizures, retinopathy of prematurity, infection morbidity, anemia
requiring blood transfusion, neonatal surgery, hyperbilirubinemia,
neurological morbidity, or death prior to hospital discharge) (Am J Obstet

Gynecol. 2017 Oct;217(4):478.e1-478.e8. doi: 10.1016/j.ajog.2017.05.050.)



Breastfeeding? 2.5% transmission rate (Obstet Gynecol. 2018 May;131(5):783-788.
doi: 10.1097/AOG.0000000000002575.)



In another study, median concentration of ∆9-THC was 9.47
ng/mL (Bertrand et al. Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk
Pediatrics. September 2018, VOLUME 142 / ISSUE 3)



Long-term neurobehavioral effect of exposure to delta9-tetrahydrocannabinol on the developing brain is
unclear. (some anatomical findings such as increased cortical thickness but
unclear if any clinical significance)

